[Enhanced antitumor action of 5-fluorouracil when used in combination with 4-methylmercaptopyrazolo[3,4-d]pyrimidine 1-nucleoside].
Mice BDF1 with L 1210 or mice BALB/c with plasmacytoma MOPS-406 after pretreatment with ineffective doses of 1-beta-D-ribofuranosyl-4-methylmercaptopyrazolo(3,4-d)pyramidin e (25 to 100 mg/kg per 5 days) were treated with 5-fluorouracil at the optimal dose 100 mg per day. This combination produced a 1.5-2-fold or 2 to 4 fold enhancement of the antitumour effect of 5-fluorouracil without simultaneous increase of lethal toxicity.
Lobova
T G
TG
Korbukh
I A
IA
Preobrazhenskaia
M N
MN
Garin
A M
AM
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D007939:Leukemia L1210 / Q000188:drug therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010954:Plasmacytoma / Q000188:drug therapy; D013872:Thionucleosides / Q000008:administration & dosage
D013872:Thionucleosides; C043416:1 beta-ribofuranosyl-4-(methylmercapto)pyrazolo(3,4-d)pyrimidine; D005472:Fluorouracil
Povyshenie protivoopukholevogo deĭstviia 5-ftoruratsila pri kombinirovannom primenenii s 1-nukleozidom 4-metilmerkaptopirazolo[3,4-d]pirimidina.